In a research report issued today, MLV analyst George Zavoico maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised his price target …
In a research report released Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $32 price …
In a research report sent to investors today, Cowen analyst Boris Peaker initiated coverage on Keryx Biopharmaceuticals (NASDAQ:KERX) with an Outperform rating and a $25 …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised his …
In a research report sent to investors today, H.C.
In a research report published Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …
In a research report released today, H.C.
Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, which represents a potential upside of 53% …
